Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance

Prior treatment

• 2\. Adverse events (except alopecia of any degree) of CTCAE \> grade 1 due to prior treatment (e.g., adjuvant chemotherapy, radiotherapy, etc.) prior to the first dose.
• 3\. History of stroke or intracranial hemorrhage within 6 months prior to the first dose.
• 8\. Refractory nausea and vomiting, chronic gastrointestinal disease, difficulty swallowing drugs, or inability to adequately absorb sunvozertinib or anlotinib due to previous bowel resection.
• 9\. Live vaccine was given 2 weeks before the first medication.

Other illness

• 1\. History of other malignant tumors within 2 years.
• 4\. The presence of any severe or poorly controlled systemic disease, including poorly controlled hypertension and active bleeding in the judgment of the investigator.
• 5\. Subjects with persistent or active infection, including but not limited to hepatitis B (HBV), hepatitis C (HCV), human immunodeficiency virus (HIV) and COVID-19 infection.
• 6\. Heart-related diseases or abnormalities
• 7\. Past history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis requiring steroid therapy or interstitial lung disease with active clinical symptoms, immune pneumonia caused by immunotherapy.
• 11\. Hypersensitivity to the test drug and the ingredients.
• 12\. Other conditions assessed by the investigator to be unsuitable for participation in the study.

Other

• 10\. Women who are breastfeeding or pregnant.

• 1\. Understand the requirements and contents of the clinical trial, and provide a signed and dated informed consent form.
• 2\. Age ≥ 18 years.
• 3\. Histopathology is confirmed non-small cell lung cancer .
• 4.Patients with advanced non-small cell lung cancer (NSCLC) who experienced small cell transformation after EGFR-TKI resistance.
• 5\. Predicted survival ≥ 12 weeks. .
• 6\. ECOG 0-2.
• 7\. Adequate bone marrow hematopoiesis and organ function.